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Abstract 
 
       We investigated the curative effect of Pheretima aspergillum (earthworm, PA) on rats with middle cerebral 
artery occlusion (MCAo). The MCAo-induced cerebral infarction was established and its underlying mechanisms by 
counting the infarction areas and evaluating the rats’ neurological status. Immunostaining was used to test the expression 
of NeuN, and glial fibrillary acidic (GFAP), S100B, and brain-derived neurotrophic factor (BDNF) proteins.  Our results 
showed that oral administration of PA for two weeks to rats with MCAo successfully reduced cerebral infarction areas in 
the cortex and striatum, and also reduced scores of neurological deficit. The PA-treated MCAo rats showed greatly 
decreased neuronal death, glial proliferation, and S100B proteins in the penumbra area of the cortex and in the ischemic 
core area of the cortex, but BDNF did not changed. These results demonstrated novel and detailed cellular mechanisms 
underlying the neuroprotective effects of PA in MCAo rats  
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Introduction 
 
      “Stroke” refers to a sudden loss of neurological function induced by an acute interruption in the blood supply to the 
brain. Either the entire brain or specific local tissues may be affected. The economic cost of stroke ranks high on the list of 
health insurance spending in both the United States and Taiwan. Stroke patients encounter a variety of functional deficits, 
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such as unconsciousness or the impairment of motor, sensory, cognitive, and language abilities. The etiological classification 
of stroke is subgrouped according to the occlusive and hemorrhagic types. In clinical practice, patients with ischemic stroke 
are usually treated with tissue plasminogen activity (tPA) to reduce thrombosis in brain arteries. This treatment is highly 
effective in restoring consciousness, but may induce serious side effects (Krakovsky et al., 2011). Intracerebral hemorrhage is 
one of the major symptoms associated with morbidity and mortality in stroke patients (Patil et al., 2012).  
      Glial fibrillary acidic protein (GFAP) is a marker of astrocytes, which are potentiated by epilepsy and stroke 
processes (Foerch et al., 2006; Lin and Hsieh, 2011). Glial cells and astrocytes may be implicated in pain sensation, stroke, 
and epilepsy processes, and astrocytes have been found to release neurotransmitters to modulate neuron excitability (Pasti 
et al., 1997). The S100B proteins are known to increase the concentration of intracellular free calcium (Barger and Van 
Eldik, 1992); S100B proteins have a low molecular weight and possess calcium-binding properties (Donato, 1999). These 
proteins are distributed in many tissues and affect protein phosphorylation, cytoskeletal function, and intracellular calcium 
homeostasis (Donato, 1999). S100B proteins are highly expressed in the brain and primary sensory neurons, including the 
trigeminal and dorsal root ganglia (Rickmann and Wolff, 1995; Ichikawa et al., 1997). S100B has several regulatory 
effects on cell proliferation, division, and metabolism, and may be upregulated in kainic acid (KA)-induced epilepsy (Lin 
and Hsieh, 2011; Liu et al., 2012). S100B protein levels may also increase during stroke-induced ischemia, and may 
therefore serve as a marker of neuronal injury (Hu et al., 2010).  
      Nerve growth factor (NGF) was the first nervous system growth factor to be identified in the 1950s; since then, 
more than 50 similar growth factors that influence neural functioning have been discovered. NGF affects neuronal 
survival, growth, and maturation, as well as neurite outgrowth and branches (Levi-Montalcini and Hamburger, 1951; 
Hyman et al., 1991). Other nervous system growth factors that have been suggested as potential neuroprotective drugs for 
neurological and psychiatric disorders include brain-derived neurotrophic factor (BDNF), glial cell line-derived 
neurotrophic factor (GDNF), and neurturin. BDNF is used to treat many neurological disorders with associated dementia, 
including Parkinson’s disease and Alzheimer’s disease (Tuszynski et al., 2005; Nagahara and Tuszynski, 2011). One study 
found that BDNF bound with tropomyosin-related kinase receptor type B (TRKB) and further induced mitogen-activated 
protein kinases (MEKs), extracellular signal-regulated kinases 1/2 (ERK1/2), or alternatively PI3K-AKT pathways 
(Kordower et al., 1999). 
      Traditional Chinese Medicine (TCM) has been used in China for thousands of years. One of the medicines 
administered by TCM doctors is Pheretima Aspergillum (PA), a cold and salty material derived from the earthworm. The 
body of the PA is filled with fluid containing potent biological agents such as growth factor, adhesion, and 
hemoglutination molecules. Wei et al reported that the extract of PA promoted the regeneration of injured peripheral 
nerves (Wei et al., 2009). In clinical practice, PA has long been recognized for its curative effects in the treatment of 
epilepsy, and the therapeutic effects of PA in stroke and epilepsy patients have been well documented, as have its 
anti-coagulative properties. However, limited data exist on the detailed mechanisms of PA. Recent research demonstrated 
that PA induces anti-coagulative activity (Hrzenjak et al., 1998) and anti-oxidative effects (Grdisa et al., 2001). In addition, 
PA can enhance Schwann cell migration and proliferation as a nerve regeneration medication (Chang et al., 2011a). 
      We investigated the curative effects and cellular mechanisms of PA when used to treat cerebral infarction induced 
by middle cerebral artery occlusion (MCAo). We tested whether PA could protect against MCAo-induced cerebral 
infarction and its associated cortex neuronal death, using immunohistochemistry to verify the role of PA in 
MCAo-induced cerebral infarction. The expression of GFAP, S100B protein, and BDNF were compared between control, 
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MCAo, and PA-treated groups. Overall, oral administration of PA attenuated the infarction areas by attenuating GFAP 
and S100B protein levels. 
 
Material and methods 
Animals 
 
      Male Sprague-Dawley (SD) rats, each weighing 300 g to 350 g, were used in this study.  Use of these 
animals was approved by the Institute of Animal Care and Use Committee of China Medical University, and our research 
followed the Guide for the Use of Laboratory Animals (National Academy Press). Our research comprised 2 experiments, 
namely, Experiments A and B, as described in Section 2.3 below. Experiment A included 30 rats divided into 5 groups, 
each containing 6 rats. Eighteen rats were studied in Experiment B, divided into 3 groups, each containing 6 rats. During 
the experiment, the rats were denied food overnight but had free access to water. 
 
Preparation of PA  
 
      The PA [Megascolecidae, Pheretima aspergillum (E. perrier)] used in this study was produced in the Guangxi 
province of China. The origin of the PA was authenticated, and the material was examined by Sun Ten Pharmaceutical Co. 
Ltd. in Taiwan for microorganisms, heavy metals, and pesticide, according to the accepted standards of good 
manufacturing practice in Taiwan. The extract of PA was produced by boiling 1 kg of dried PA with 14 L of distilled 
water for 1 h. The mixture was then concentrated into 1.33 kg/kg. The concentration of the PA solution was identified by 
sodium dodecyl sulfate polyacryamide gel electrophoresis using lumbrokinase (BOLUCKE, Canada) as a standard. These 
assessments were performed by Sun Ten Pharmaceutical Co. Ltd. (Taiwan). The final solution of PA was prepared as 1.0 
g/ml. 
. 
Establishment of MCAo model 
     
      The MCAo animal model was established in SD rats through an intraluminal suture method, as previously 
described (Cheng et al., 2008; Lin and Hsieh, 2010). Rats were anesthetized with chloral hydrate (400 mg/kg, i.p.), and the 
right common carotid artery (CCA) and the internal carotid artery (ICA) were exposed through a neck midline incision. 
This was followed by ligation of the pterygopalatine artery close to its branch. A 3-0 nylon filament suture, blunted at the 
tip by a flame and coated with poly-L-lysine (Sigma, USA), was inserted into the right external carotid artery through the 
CCA and up to the ICA, a distance of 20 mm to 25 mm, to block the origin of the right middle cerebral artery (MCA). The 
suture was removed slowly 15 min after the occlusion, to re-establish blood flow.  
Our study consisted of two experiments. Experiment A focused on the curative effects of PA on cerebral infarction and 
neurological status, and experiment B used immunohistochemistry staining to examine the precise curative mechanism of 
PA.  
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Grouping of rats, and evaluation of neurological status 
 
      At the start of the research, the rats were randomly divided into 5 groups as follows: 1) the sham group, which 
received neither MCAo nor PA treatment; 2) the control group, which underwent MCAo without treatment by PA; 3) the 
PA 0.25 group, which underwent MCAo and received daily oral treatment with 0.25 g PA per kg of body weight; 4) the 
PA 0.5 group, which underwent MCAo and received 0.5 g PA/kg daily; and 5) the PA 1.0 group, which underwent MCAo 
and received 1.0 g PA/kg daily. Groups when the scores ≧ 7 except sham groups (without MCAo and without PA). The 
rats’ neurological status was evaluated at three separate time points after MCAo manipulation, namely 24 h, day 8, and 
day 15. The PA was orally administered immediately after the first evaluation and treatment was continued for 2 weeks, 5 
days per week. At the end of this period, on day 15, the rats’ neurological statuses were evaluated and the animals were 
then sacrificed and their brains were removed. Neurological status was evaluated in each rat by assessing the motor, 
sensory, balancing, and reflex functions. The maximum possible neurological score was 18, as described in our previous 
studies (Lin and Hsieh, 2010). 
 
Measurement of infarction area 
 
      Each rat brain was sectioned into 2 mm slices according to a brain matrix, immediately after removal. The samples 
were placed in a 2% solution of 2,3,5-triphenyl tetrazolium chloride (TTC, Merk, Germany) for 15 min at 37 °C, as 
described in our previous report (Lin and Hsieh, 2011). The results produced a white area representing infarction, and 
red-purple, indicating areas not affected by infarction. We also calculated a brain tissue ratio to represent the degree of 
shrinkage, using an Image analysis system (Image J 1.42a, National Institute of Health, USA). This ratio was calculated as 
total area (infarction plus non-infarction areas) of the right hemisphere divided by total area of the left hemisphere, and 
was presented as a percentage (%).  
 
Immunohistochemistry staining 
 
      The rats were randomly divided into the control, PA 0.5 groups when the scores of neurological deficit ≧ 7 except 
sham group at 24 h after MCAo manipulation. On day 15 after MCAo manipulation, the animals were deeply anesthetized 
with chloral hydrate (400 mg/kg, i.p.), and perfused with normal saline through the cardiac vascular system, followed by 
infusion with 4% paraformaldehyde (Merck, Frankfurt, Germany) in 0.1M phosphate buffered saline (PBS, pH = 7.4). 
The brains were removed and placed in the same fixative and stored overnight at 4 °C. After being washed briefly with 
PBS, the brains were transferred to 30% sucrose in 0.01 M PBS for cryoprotection. Thereafter, coronal sections containing 
the hippocampal area were cut into 20 μm slices using a cryosectioning technique. The sections were pre-incubated (for 2 
h at 25 °C) with a mixture of 10% horse serum and 0.3% Triton X-100 in PBS, to avoid non-specific binding. Sections 
were then incubated overnight at 4 °C with a mixture of rat monoclonal antibody against GFAP (1:200; Oncogene, USA), 
NeuN (1:1000; Chemicon, USA), and BDNF (1:1000; Millipore, Temecula, USA) in a PBS with 0.1% horse serum and 
0.1% Triton X-100. Sections were subsequently incubated (for 2 h at 25 °C) with biotinylated-conjugated secondary 
antibody (1:200 diluted; Vector, Burlingame, CA, USA), and were then further incubated with avidin-horseradish 
peroxidase complex (ABC-Elite, Vector). The sections were washed three times with PBS between each incubation step, 
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for 10 min per wash. Finally, the sections were visualized using 3,3’-diaminobenzidine as the chromogen. 
 
Statistical analysis 
 
      All statistic data are presented as the mean ± standard error. Statistical significance between sham, control, and PA 
group was tested using the ANOVA test, followed by a post hoc Tukey’s test (p < 0.05 was considered statistically 
significant). 
 
 
Results 
Curative effects of PA on MCAo-induced cerebral infarction  
 
      Our results revealed that the curative effects of PA on MCAo-induced stroke in rats were the result of reduced 
infarction areas, with an associated decrease in the scores of neurological deficit. Stroke is a major clinical disease 
resulting from inadequate blood supply to the brain. We induced an in vivo animal model of stroke in SD rats, as 
previously described (Lin and Hsieh, 2010). Substantial neurological malfunctioning which resembled that of stroke was 
successfully induced in the rats. Each experimental group contained 6 animals, namely, S-1 to S-6, with brain sections 
derived as shown in Figure 1a. In the sham group, no significant infarction volume was found across whole brain tissue. In 
the groups receiving MCAo manipulation, the rat brains were severely damaged, with severe ischemia-induced infarction 
areas. Figure 1b illustrates the quantification of the infarction areas in the penumbra and ischemic core areas of the cortex, 
and the ischemic core area of the striatum. Oral administration of PA significantly reduced the infarction areas, with lower 
PA concentrations of 0.25 g/kg to 0.5 g/kg being more effective than 1 g/kg PA (83.51.7%, 83.43.3%, and 75.53.1% 
compared with the sham group, for doses of 0.25 g/kg, 0.5 g/kg, and 1 g/kg PA, respectively), whereas control group was 
73.34.1%. All data were statistically analyzed and the results are presented in Figure 2a. Oral PA significantly reduced 
MCAo-induced neurological deficits, as shown in Figure 2b. 
 
Oral administration of PA modulated neuron survival of GFAP and S100B  
     
      Our results indicated that MCAo-induced cerebral infarction was present in the penumbra area of the cortex. Oral 
administration of PA reversed MCAo-induced ischemia, and modulated neuron survival of GFAP and S100B in the 
penumbra area of the cortex. We attempted to identify MCAo-mediated stroke and the curative effect of PA and its 
underlying mechanisms. We found that neurons in the penumbra area of the cortex survived in a healthy state in rats 
receiving a sham operation (637.211.4 neurons per field, n=6) (Figure 3a). Notably, in the MCAo group, NeuN-positive 
immunostaining was decreased, as was the infarction area (155.35.9 neurons/field, n=6) (Figure 3b). Our results showed 
that NeuN immunostaining was significantly recovered with the administration of 0.5 g/kg PA (321.240.1 neurons/field, 
n=6) (Figure 3c).  
      GFAP is a marker of astrocytes, which increase during epileptogenesis and stroke. We investigated the role of 
GFAP in PA treatment. Importantly, MACo-induced ischemia dramatically increased the expression of GFAP in the 
penumbra area of the cortex (from 5.31.4 to 163.521.7 astrocyte/field, n=6) (Figures 3d and 3e). The increase in GFAP 
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was ameliorated after 0.5 g/kg PA administration for 2 weeks (35.05.7 astrocyte/field, n=6) (Figure 3f). We also 
attempted to verify the role of S100B in PA-treated rats with MCAo, because S100B is a marker of brain injury, including 
acute ischemic stroke. Our results showed that S100B was highly augmented under MCAo-induced stroke (from 9.33.0 
to 152.722.4 cells/field, n=6) (Figures 3g and 3h). This phenomenon was reversed by the oral administration of PA for 2 
weeks, implying a pathway of PA mechanism (108.221.2 cells/field, n=6) (Figure 3i). We next tested the possible 
involvement of BDNF in MCAo-induced stroke.  
 
Oral administration of PA modulated BDNF proteins in the penumbra and ischemic core of the cortex. 
 
      Our results revealed that oral administration of PA modulated BDNF proteins in the penumbra area and the 
ischemic core area of the cortex. The BDNF in the penumbra was slightly increased in the MCAo rats compared with the 
sham group (from 1.30.8 to 33.78.8 cells/field, n=6) (Figures 4a and 4b). The expression of BDNF was not 
significantly upregulated after PA administration (33.512.1 cells/field, n=6) (Figure 4c). The appearance of BDNF in the 
ischemic core of the cortex was slightly increased in the MCAo group (from 0.80.5 to 40.07.2 cells/field, n=6) (Figures 
4d and 4e), but was not altered by 2 weeks of oral PA treatment (32.211.1 cells/field, n=6) (Figure 4f).  
 
Oral PA decreased GFAP and S100B in the ischemic core area of the cortex 
    
      We then tested the effect of PA on MCAo-mediated stroke and its related signaling mechanisms. Neuron survival 
in the cortex was downregulated after MCAo treatment, indicating damage to cortex neurons (from 630.89.2 to 
61.714.3 neurons/field, n=6) (Figures 5a and 5b). Similarly, curative effects were visible in the cortex after 2 weeks of 
PA administration (208.751.2 neurons/field, n=6) (Figure 5c). The GFAP expression patterns in the cortex were similar 
to that in the penumbra area of the cortex, with the MCAo group showing increased expression compared with the sham 
group (from 7.82.3 to 79.214.6 astrocyte/field, n=6) (Figure 5d and 5e). The phenomenon was reversed with 2 weeks of 
PA treatment, as shown in Figure 5f (54.75.6 cells/field, n=6). Figure 5g shows the normal distribution of S100B 
expression, which was upregulated in MCAo-induced ischemia as illustrated in Figure 5h (from 10.73.1 to 111.217.5 
cells/field, n=6). Figure 5i shows the role of PA in reversing MCAo-induced ischemia (75.710.3 cells/field).  
 
The effect of PA treatment on neuron survival, GFAP and S100B in the ischemic core area of the striatum. 
 
      We investigated whether oral PA could increase neuron survival and BDNF expression while simultaneously 
decreasing GFAP and S100B overexpression. Our results demonstrated that the number of striatum neurons was from 
7.20.9 to 11.82.2 (cells/field, n=6) after MCAo (Figures 6a and 6b). This pattern was not altered by oral PA treatment 
(13.83.6 cells/field, n=6) (Figure 6c). Similar results were obtained for GFAP expression, which increased as a result of 
MCAo (from 5.31.1 to 52.025.6 cells/field, n=6) (Figures 6d and 6e), but the basic pattern did not appear to be affected 
by PA treatment (73.323.0 cells/field, n=6) (Figure 6f). The expression phenomena of S100B were coordinative to 
GFAP as increasing in MCAo group (from 7.31.4 to 49.314.2 cells/field, n=6) (Figures 6g and 6h), with no significant 
changes being found after PA administration (46.211.3 cells/field, n=6) (Figure 6i). Furthermore, the density of BDNF 
was higher in the MCAo group (from 0.50.5 to 7.81.1 cells/field, n=6) in the striatum areas (Figures 6j and 6k), but the 
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results were similar for the control and PA groups (10.82.6 cells/field, n=6) (Figure 6).  
 
 
Figure 1: MCAo-induced cerebral infarction areas in whole brains, illustrating the quantity of proteins in cortex and striatum. 
(a) MCAo-induced ischemia areas within six individual rat brain slices in the sham, control, and PA treatment 
groups. (b) Illustration of investigation of selected proteins in penumbra areas of the cortex, ischemia core areas of 
the cortex, and ischemia core of the striatum. Dotted areas= 1.0 mm2. 
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Figure 2: The cerebral infarction areas and scores for neurological deficit in the sham, control, and PA treatment 
groups (0.25 g/kg, 0.5 g/kg, and 1g/kg). (a) The ratio of shrunken area compared with the sham group (Sham). (b) 
MCAo-induced neurological deficit scores for each group were recorded on days 1 (D1), 8 (D8), and 15 (D15) after MCAo. 
* P < .05 compared with the sham group. ** P < .01 compared with sham group. ## P < .01 compared with control group 
(Con). 
 
 
Liu et al., Afr J Tradit Complement Altern Med. (2013) 10(1):66-82 
http://dx.doi.org/10.4314/ajtcam.v10i1.11 
74
 
Figure 3: Immunostaining of hematoxylin and eosin (HE), NeuN, GFAP, and S100B in penumbra area of the cortex of sham, 
control, and 0.5 g/kg PA-treated groups. HE (blue) and NeuN (brown) positive staining in penumbra area of the 
cortex in sham (a), control (b), and 0.5 g/kg PA (c) groups. HE (blue) and GFAP (brown) positive stained cells in 
sham (d), control (e), and 0.5 g/kg PA (f) groups. HE (blue) and S100B (brown) positive stained cells in sham (g), 
control (h), and 0.5 g/kg PA (i) groups. The arrows indicate positive staining. The pictures were captured at 100 x 
magnification. 
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Figure 4: Immunostaining of hematoxylin and rosin (HE) and BDNF in the penumbra area and ischemic core of the 
cortex of sham, control, and 0.5 g/kg PA-treated groups. HE (blue) and BDNF (brown) positive staining in 
penumbra area of the cortex in sham (a), control (b), and 0.5 g/kg PA (c) groups. HE (blue) and BDNF (brown) 
positive staining in ischemic core of the cortex in sham (d), control (e), and 0.5 g/kg PA (f) groups. The arrows 
indicate positive staining. The pictures were captured at 100 x magnification.  
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Figure 5: Immunostaining of hematoxylin and eosin (HE), NeuN, GFAP, and S100B in the ischemic core of the cortex in 
sham, control, and 0.5 g/kg PA-treated groups. HE (blue) and NeuN (brown) positive stained cells in ischemic core 
area of the cortex in sham (a), control (b), and 0.5 g/kg PA (c) groups. HE (blue) and GFAP (brown) positive 
stained cells in sham (d), control (e), and 0.5 g/kg PA (f) groups. HE (blue) and S100B (brown) positive stained 
cells in sham (g), control (h), and 0.5 g/kg PA (i) groups. The arrows indicate positive staining of cells. The pictures 
were captured at 100 x magnification. 
Liu et al., Afr J Tradit Complement Altern Med. (2013) 10(1):66-82 
http://dx.doi.org/10.4314/ajtcam.v10i1.11 
77
 
 
Figure 6: Immunostaining of hematoxylin and eosin (HE), NeuN, GFAP, S100B, and BDNF in ischemic core of the striatum 
in sham, control, and 0.5 g/kg PA-treated groups. HE (blue) and NeuN (brown) positive stained cells in ischemic 
core of the striatum in sham (a), control (b), and 0.5 g/kg PA (c) groups. HE (blue) and GFAP (brown) positive 
stained cells in sham (d), control (e), and 0.5 g/kg PA (f) groups. HE (blue) and S100B (brown) positive stained 
cells in sham (g), control (h), and 0.5 g/kg PA (i) groups. HE (blue) and BDNF (brown) positive staining cells in 
sham (j), control (k), and 0.5 g/kg PA (l) groups. The arrows indicate positive staining. The pictures were captured 
at 100 x magnification. 
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Figure 7: Interpretive Diagram. Pheretima aspergillum (PA) reduced brain atrophy and cerebral infarction in middle cerebral 
artery occlusion rats. The PA increased neuron survival, and reduced glial fibrillary acid protein (GFAP) and S100B 
protein, but PA did not change brain-derived neurotrophic factor (BDNF). 
 
 
 
Discussion 
 
      We first established a MCAo animal model with ischemia mainly in the penumbra and ischemic core areas of the 
cortex, and the ischemic core area of the striatum. We found that the effect of PA treatment on MCAo-induced ischemia 
was dose-dependent, with the most effective dose being 0.25 to 0.5 g/kg rather than 1g/kg. This finding provides evidence 
for the curative effect of Chinese herbal PA in reducing infarction volume. We further examined the detailed mechanisms 
underlying the effect of PA. We provide novel evidence that neuronal survival was downregulated by MCAo 
manipulation, but was reversed to the normal state after oral PA administration. GFAP and S100B were overexpressed 
after MCAo but were ameliorated by PA administration (summarized in Figure 7).  
      Stroke is one of the major syndromes observed in clinical emergencies, and carries a high cost for both patients 
and medical staff. Many physical and physiological markers are involved in the diagnosis of stroke, including GFAP and 
S100B levels. S100B is a calcium-binding protein mainly found in glial cells. The overexpression of S100B has been 
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shown to have neurotoxicity with calcium toxicity, and an increase in S100B is highly associated with hematoma volume 
(Delgado et al., 2006). Recent studies have suggested that GFAP and S100B could be biomarkers for acute stroke (Foerch 
et al., 2012). Our previous study demonstrated an increment in GFAP and S100B in hippocampal CA1 and CA3 due to 
kainic acid-induced epilepsy (Lin and Hsieh, 2011; Liu et al., 2012). GFAP is mainly a brain-specific intermediate 
filament protein involved in glial cell morphology and migration. GFAP is rarely secreted by cells under normal 
physiological conditions, and is not detectable in the plasma of healthy humans (Missler et al., 1999). However, large 
amounts of GFAP are released in acute ischemia stroke patients (Wunderlich et al., 2004). Datta et al reported that GFAP 
was increased at 24 h after ischemic reperfusion injury, indicating the negative effect of GFAP (Datta et al., 2011). The 
current study found that oral administration of 0.5 g/kg PA successfully reduced the ischemic areas and neurological 
deficit in MCAo rats. This curative effect was accompanied by attenuating the overexpression of GFAP and S100B 
proteins. These novel mechanisms of PA have potential for both experimental and clinical applications. PA can increase 
growth associated protein 43 (GFP 43) and synapsin I in PC12 cell, and also can increase success percentage in rat with a 
10 mm sciatic nerve defect. Therefore, PA can enhance the regeneration of peripheral nerve (Chen et al., 2010). The PA 
mediates through extracellular signal regular protein (ERK1/2) and p38 of MAPK signaling pathway to induce  the 
expression of matrix degrading proteolytic enzymes, and metalloproteinase (MMP) 2 and MMP 9 to promote the 
migration and regeneration of Schwann cells (Chang et al., 2011b). The main mechanism of PA enhancing Schwann 
regeneration is depending on P13K protein (Change et al., 2011c). 
      Recently, BDNF has been suggested as having therapeutic potential for several diseases, including Alzheimer’s 
disease and Parkinson’s disease. Several studies have demonstrated that BDNF ameliorated cell death and potentiated 
neuronal functioning. Hyman et al reported that BDNF supported the survival of dopaminergic neurons in the substantia 
nigra (Hyman et al., 1991). In patients with Parkinson’s disease, BDNF expression was downregulated in the substantia 
nigra, indicating a key role of BDNF in the disease (Hyman et al., 1991). BDNF may also promote neuron survival and 
neurite outgrowth (Mogi et al., 1999). The current study investigated the curative effect of oral PA in MCAo-induced 
ischemic rats. Our results indicated that the therapeutic function was not due to augmenting the density of BDNF in the 
penumbra area of the cortex, the ischemic core area of the cortex, and the ischemic core area of the striatum. These novel 
results are dramatic and interesting, and illustrate the important therapeutic effects of PA as administered by traditional 
Chinese doctors. 
Conclusions 
 
      We found that treatment with PA significantly improved rats’ neurological and functional recovery after MCAo. 
Treatment with PA was also associated with increased density of neurons, and reduced GFAP and S100B astrocyte 
activation.  
 
Glossary 
UR, Uncaria Rhynchophylla; PA, Pheretima aspergillum; MCAo, middle cerebral artery occlusion; GFAP, glial fibrillary 
acidic protein; BDNF, brain-derived neurotrophic factor; tPA, tissue plasminogen activity; KA, kainic acid; NGF, Nerve 
growth factor; TRKB, tropomyosin-related kinase receptor type B; MEKs, mitogen-activated protein kinases; ERK1/2, 
extracellular signal-regulated kinases 1/2; TCM, Traditional Chinese Medicine; SD, Sprague-Dawley. 
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